Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 12.79% is in line with its 5-year average of 13.23%, around the middle of its 5-year range (4.54%–20.47%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.53% below its 12-month average of 17.90%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.79%.
DEBT TO ASSETS RATIO
12.79%
DEBT TO ASSETS RATIO AVG TTM
17.90%
DEBT TO ASSETS RATIO AVG 3Y
15.60%
DEBT TO ASSETS RATIO AVG 5Y
13.23%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-28.53%
CURRENT VS 3Y AVG
-18.01%
CURRENT VS 5Y AVG
-3.37%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 812 covered companies
CURRENT VS SECTOR MEDIAN
+14110.38%
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$510.83M
Debt to Assets Ratio
12.79%
TTM Avg
17.90%
3Y Avg
15.60%
5Y Avg
13.23%
Market Cap
$504.79M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$521.32M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$498.49M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$523.35M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $510.83M | 12.79% | 17.90% | 15.60% | 13.23% |
| 908 Devices Inc. (MASS)vs › | $511.61M | 0.02% | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.33M | 0.07% | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.79M | 0.01% | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $521.32M | 0.00% | N/A | N/A | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $498.49M | 0.05% | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $523.35M | 0.00% | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $494.94M | 0.01% | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $490.20M | 0.66% | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $531.60M | 0.19% | N/A | N/A | N/A |
Debt/Assets
12.8%
Debt/Equity
0.16
Current Ratio
10.72
Interest Coverage
-192.5x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 12.79% |
| 2026-03-31 | 20.47% |
| 2025-12-31 | 20.02% |
| 2025-09-30 | 19.36% |
| 2025-06-30 | 16.84% |
| 2025-03-31 | 16.00% |
| 2024-12-31 | 16.54% |
| 2024-09-30 | 14.45% |
| 2024-06-30 | 14.56% |
| 2024-03-31 | 16.35% |
| 2023-12-31 | 14.80% |
| 2023-09-30 | 13.57% |
| 2023-06-30 | 11.91% |
| 2023-03-31 | 13.35% |
| 2022-12-31 | 12.31% |
| 2022-09-30 | 10.90% |
| 2022-06-30 | 10.37% |
| 2022-03-31 | 7.16% |
| 2021-12-31 | 6.96% |
| 2021-09-30 | 4.69% |
| 2021-06-30 | 4.54% |
| 2021-03-31 | 4.38% |
| 2020-12-31 | 4.38% |
| 2020-09-30 | 4.16% |
| 2020-06-30 | 4.06% |
| 2020-03-31 | 7.49% |
| 2019-12-31 | 7.39% |
| 2019-09-30 | 5.42% |
| 2019-06-30 | 4.75% |
| 2019-03-31 | 4.65% |
| 2018-12-31 | 4.45% |
| 2018-09-30 | 37.97% |
| 2018-06-30 | 0.00% |
